Vilon
$Ultrashort thymic bioregulator; Mostly Russian/Eastern European preclinical and low-certainty clinical literature
Vilon is a two-amino-acid peptide: lysine plus glutamic acid, abbreviated Lys-Glu or KE. It is usually marketed as a thymus/immune-aging bioregulator. It is not the same as thymosin alpha-1, thymalin, thymogen, or hCG/hMG.
Vilon has a real paper trail, but much of it is old, small, Russian-language, cell-culture, animal, or single-research-network literature. It is better understood as an immune and gene-expression research peptide, not as a proven rejuvenation or cancer-prevention therapy. Focus on identity and evidence quality.
Separate three claims: immunomodulation, chromatin/gene-expression effects, and lifespan/tumor findings in animals. These are related hypotheses, not a single proven human outcome.
Classification details
- Vilon is L-lysyl-L-glutamic acid, a synthetic dipeptide usually written as Lys-Glu or KE.
- PubChem lists lysylglutamic acid with formula C11H21N3O5 and molecular weight about 275.30 g/mol.
- Some databases also list lysylglutamic acid dihydrate under names such as Lys-Glu dihydrate, lysine glutamate dihydrate, and Vilon dihydrate.
- Vilon is part of the short-peptide or Khavinson bioregulator family, a group of ultrashort peptides studied mainly for tissue-specific regulation, gene expression, chromatin organization, immune signaling, and aging-related models.
- Vilon is generally framed as thymic or immunomodulatory, while Epithalon is pineal/telomere-oriented, Thymogen is Glu-Trp, and Thymalin is a broader thymic peptide complex rather than a single dipeptide. Because Vilon contains only two amino acids, it does not behave like a large protein hormone.
- Its proposed biology is less about receptor saturation and more about short-peptide signaling, gene-expression effects, or cellular regulatory models. Those mechanisms remain incompletely validated by modern human pharmacology.
- Vilon is a short dipeptide bioregulator associated with immune and aging claims in regional literature. It is not a proven geroprotective drug.
- The central Vilon hypothesis is immunomodulation.
- Older and newer studies describe effects on thymus-cell culture, splenocytes, interleukin-2 expression, T-cell-related activity, macrophage/monocyte behavior, cytokine signaling, and inflammatory adhesion pathways.
- The common claim is not blanket immune stimulation. It is immune normalization or modulation.
- A second hypothesis is gene-expression and chromatin regulation.
- Some short-peptide literature reports changes in chromatin decondensation, ribosomal-gene activity, DNA-microarray expression patterns, and other epigenetic-like effects.
- These findings are interesting but warrant careful interpretation, because many studies are small, model-specific, and not independently replicated at modern drug-development standards.
- Vilon is not a direct cytokine drug, antiviral, vaccine substitute, or immune-booster supplement.
- The more careful statement is that Lys-Glu has been studied as an ultrashort bioregulator that may influence immune-cell signaling and gene-expression patterns in experimental systems.
- Proposed mechanisms include gene-expression modulation and thymic/immune bioregulation. These are broad hypotheses or regional research findings, not settled conclusions.